Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Entry into a Material Definitive Agreement
16 Apr 24
8-K
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
1 Apr 24
S-8
Registration of securities for employees
29 Feb 24
8-K
Entry into a Material Definitive Agreement
29 Feb 24
424B5
Prospectus supplement for primary offering
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
22 Feb 24
8-K
Regulation FD Disclosure
4 Jan 24
8-K
Entry into a Material Definitive Agreement
4 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
18 Dec 23
8-K
Other Events
6 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
7 Nov 23
8-K
Other Events
21 Aug 23
8-K
Departure of Directors or Certain Officers
8 Aug 23
8-K
Departure of Directors or Certain Officers
3 Aug 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
8-K
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business
1 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 23
10-Q
2023 Q1
Quarterly report
2 May 23
8-K
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
2 May 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
8-K
Other Events
10 Mar 23
S-3ASR
Automatic shelf registration
2 Mar 23
S-8
Registration of securities for employees
2 Mar 23
10-K
2022 FY
Annual report
1 Mar 23
8-K
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
1 Mar 23
8-K
Regulation FD Disclosure
9 Jan 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
8 Nov 22
8-K
Termination of a Material Definitive Agreement
3 Nov 22
8-K
Other Events
15 Sep 22
424B5
Prospectus supplement for primary offering
15 Sep 22
424B5
Prospectus supplement for primary offering
14 Sep 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
Latest ownership filings
SC 13D/A
PERCEPTIVE ADVISORS LLC
17 Apr 24
4
Yann Mazabraud
16 Apr 24
4
Christopher Paul German
3 Apr 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
3 Apr 24
4
Joseph Shulman
22 Mar 24
4
Jennifer Kayden Lee
22 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
SC 13D
PERCEPTIVE ADVISORS LLC
20 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Hunter C Smith
19 Mar 24
4
Joseph Shulman
19 Mar 24
4
David P Meeker
19 Mar 24
4
Yann Mazabraud
19 Mar 24
4
Jennifer Kayden Lee
19 Mar 24
4
Pamela J. Cramer
19 Mar 24
4
David P Meeker
21 Feb 24
4
Yann Mazabraud
21 Feb 24
4
Christopher Paul German
21 Feb 24
4
Pamela J. Cramer
21 Feb 24
4
Hunter C Smith
21 Feb 24
4
Joseph Shulman
21 Feb 24
4
Jennifer Kayden Lee
21 Feb 24
4
Joseph Shulman
15 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
4
Hunter C Smith
13 Feb 24
4
Yann Mazabraud
13 Feb 24
4
Jennifer Kayden Lee
13 Feb 24
4
Joseph Shulman
13 Feb 24
4
Pamela J. Cramer
13 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G
PERCEPTIVE ADVISORS LLC
12 Feb 24
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
12 Feb 24
144
Notice of proposed sale of securities
9 Feb 24
4
Jennifer Kayden Lee
5 Feb 24
4
Hunter C Smith
5 Feb 24
4
Joseph Shulman
5 Feb 24
4
David P Meeker
5 Feb 24
4
Pamela J. Cramer
5 Feb 24
SC 13G/A
GOLDMAN SACHS GROUP INC
5 Feb 24